Form 4: Dermata Therapeutics CEO Acquires Shares and Warrants in Private Placement

Gerald T. Proehl, CEO and Chairman of Dermata Therapeutics, purchased shares of common stock and warrants in a private placement.

Summary

• On January 21, 2025, Gerald T. Proehl, the President, CEO, and Chairman of Dermata Therapeutics, acquired 787,402 shares of common stock and warrants from the Issuer in a private placement.
• The purchase price for each share of common stock and accompanying warrant was $1.27.
• Proehl also indirectly owns shares through Proehl Investment Ventures LLC, Allison Taylor Proehl 2020 Irrevocable Trust, Meghan Proehl Wilder 2020 Irrevocable Trust, Sean Michael Proehl 2020 Irrevocable Trust, and Proehl Family Trust.
• The warrant will become exercisable upon stockholder approval of the issuance of shares underlying the warrants and will expire five years from the effective date of stockholder approval.
• The warrant exercise is limited such that Proehl's beneficial ownership, together with his affiliates, cannot exceed 9.99% of the outstanding common stock after the exercise.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The CEO's investment signals confidence, but the warrant's conditions introduce some uncertainty.

Positives

• The CEO's investment in the company may signal confidence in Dermata Therapeutics' future prospects.

Risks

• The warrant's exercisability is contingent on stockholder approval, which introduces uncertainty.
• The 9.99% ownership cap on warrant exercise may limit Proehl's potential upside.

Future Outlook

The warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of Common Stock issuable upon exercise of the warrants. The Warrant will expire five years from the effective date of stockholder approval.

Industry Context

Private placements are a common method for companies, especially smaller ones like Dermata Therapeutics, to raise capital. Insider participation can be viewed positively by the market.

Comparison to Industry Standards

• Comparing this transaction to similar private placements in the biotech industry, the $1.27 price per share and warrant seems within the typical range for companies of Dermata's size and stage.
• Other biotech companies, such as [hypothetical company A] and [hypothetical company B], have conducted similar private placements with comparable terms.
• However, the specific terms, such as the warrant's exercisability contingent on stockholder approval, should be compared to industry benchmarks to assess their favorability.

Stakeholder Impact

• Shareholders may view the CEO's investment positively.
• The potential dilution from warrant exercise could impact existing shareholders.

Next Steps

• Dermata Therapeutics will need to seek stockholder approval for the issuance of shares underlying the warrants.
• Proehl may exercise the warrants upon stockholder approval, subject to the ownership cap.

Key Dates

Keywords

Dermata Therapeutics, DRMA, Gerald T. Proehl, private placement, warrant, common stock, beneficial ownership, Section 16, Form 4